This Next-Gen Obesity Drug: Can It Save Novo Nordisk?
Novo Nordisk faces intense pressure in the fast-growing obesity treatment space. This article dives into whether this...
Novo Nordisk faces intense pressure in the fast-growing obesity treatment space. This article dives into whether this...
Lilly shares moved lower after Novo Nordisk announced price cuts on leading obesity drugs, signaling a tougher compet...
Investors are watching Viking Therapeutics as its obesity drug candidate approaches key milestones. This article brea...